药品信息:
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201933113291733.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- 部分中文SYMFI LO处方资料(仅供参考)
【英文名称】SYMFI LO
【适用证】
SYMFI LO是efavirenz(EFV),非核苷类逆转录酶抑制剂和拉米夫定(3TC)和替诺福韦地索普西富马酸盐(TDF)的三种药物组合,两者都是核(t)侧逆转录酶抑制剂,并表示为 在体重至少35千克的成人和儿童患者中治疗人类免疫缺陷病毒1型(HIV-1)感染的完整方案。(1)
【用法用量】
测试:在开始和使用SYMFI LO治疗期间,应对患者进行乙型肝炎病毒感染检测,并应获得估计的肌酐清除率,尿糖和尿蛋白。(2.1)
推荐剂量:每天一次空腹服用一片,最好是在睡前服用。(2.2)
肾功能损害:不推荐CrCL低于50 mL / min的患者或需要血液透析的终末期肾病患者。(2.3)
肝功能损害:不推荐用于中度或重度肝功能损害的患者。 对轻度肝功能损害患者慎用。(2.4)
【注意事项】
SYMFI LO禁用于先前对本产品的任何成分具有超敏反应(例如Stevens-Johnson综合征,多形红斑或中毒性皮疹)的患者。(4)
与elbasvir / grazoprevir共同管理。(4)
【INDICATIONS AND USAGE】
SYMFI LO is three-drug combination of efavirenz (EFV), a non nucleoside reverse transcriptase inhibitor, and lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), both nucleo(t)side reverse transcriptase inhibitors and is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg. (1)
【DOSAGE AND ADMINISTRATION】
Testing: Prior to initiation and during treatment with SYMFI LO, patients should be tested for hepatitis B virus infection, and estimated creatinine clearance, urine glucose, and urine protein should be obtained. (2.1)
Recommended dose: One tablet taken orally once daily on an empty stomach, preferably at bedtime. (2.2)
Renal Impairment: Not recommended in patients with CrCL less than 50 mL/min or patients with end-stage renal disease requiring hemodialysis. (2.3)
Hepatic Impairment: Not recommended for patients with moderate or severe hepatic impairment. Use caution in patients with mild hepatic impairment. (2.4)
【CONTRAINDICATIONS】
SYMFI LO is contraindicated in patients with previous hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of this product. (4)
Coadministration with elbasvir/grazoprevir. (4)
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201933113291733.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- |